Cargando…

Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases

OBJECTIVES: Serum synaptic proteins levels may change with age‐related neurodegeneration, affecting their clinical implications as a disease biomarker. We aimed to investigate neuronal and astroglial markers in patients with multiple sclerosis (MS) and aquaporin‐4 antibody‐seropositive neuromyelitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Eun‐Jae, Lim, Young‐Min, Kim, Seungmi, Choi, Lynkyung, Kim, Hyunjin, Kim, Keonwoo, Kim, Hye Weon, Lee, Ji Sung, Kim, Kwang‐Kuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317646/
https://www.ncbi.nlm.nih.gov/pubmed/32495489
http://dx.doi.org/10.1002/acn3.51070
_version_ 1783550676039630848
author Lee, Eun‐Jae
Lim, Young‐Min
Kim, Seungmi
Choi, Lynkyung
Kim, Hyunjin
Kim, Keonwoo
Kim, Hye Weon
Lee, Ji Sung
Kim, Kwang‐Kuk
author_facet Lee, Eun‐Jae
Lim, Young‐Min
Kim, Seungmi
Choi, Lynkyung
Kim, Hyunjin
Kim, Keonwoo
Kim, Hye Weon
Lee, Ji Sung
Kim, Kwang‐Kuk
author_sort Lee, Eun‐Jae
collection PubMed
description OBJECTIVES: Serum synaptic proteins levels may change with age‐related neurodegeneration, affecting their clinical implications as a disease biomarker. We aimed to investigate neuronal and astroglial markers in patients with multiple sclerosis (MS) and aquaporin‐4 antibody‐seropositive neuromyelitis optica spectrum disorders (NMOSD) to compare the clinical implications of these markers according to age. METHODS: Using single‐molecule array assays, we measured neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in sera from consecutive patients with MS (n = 117) and NMOSD (n = 63). For each disease, we assessed correlations between these markers and disease severity (Expanded Disability Status Scale [EDSS]) scores according to three age groups (≤44, 45–54, and ≥55 years). RESULTS: Although serum GFAP levels were significantly higher in patients with NMOSD than those with MS, levels of both serum markers revealed significant positive correlations with EDSS scores in both diseases. In MS patients, the degrees of correlation between serum NfL (or GFAP) levels and EDSS scores were similar across all age groups. However, in NMOSD patients, positive GFAP‐EDSS correlations were distinctively stronger in the youngest than in the oldest group. Conversely, there were no positive NfL‐EDSS correlations in NMOSD in the youngest group, but there were significant in the oldest group. INTERPRETATION: The degrees to which serum NfL and GFAP levels reflect disease severity vary significantly with patient age in NMOSD, but not in MS. These findings suggest that the pathological processes and progression differ between the diseases; hence, serum biomarker levels may need to be interpreted differently according to patient age and disease type.
format Online
Article
Text
id pubmed-7317646
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73176462020-06-29 Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases Lee, Eun‐Jae Lim, Young‐Min Kim, Seungmi Choi, Lynkyung Kim, Hyunjin Kim, Keonwoo Kim, Hye Weon Lee, Ji Sung Kim, Kwang‐Kuk Ann Clin Transl Neurol Research Articles OBJECTIVES: Serum synaptic proteins levels may change with age‐related neurodegeneration, affecting their clinical implications as a disease biomarker. We aimed to investigate neuronal and astroglial markers in patients with multiple sclerosis (MS) and aquaporin‐4 antibody‐seropositive neuromyelitis optica spectrum disorders (NMOSD) to compare the clinical implications of these markers according to age. METHODS: Using single‐molecule array assays, we measured neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in sera from consecutive patients with MS (n = 117) and NMOSD (n = 63). For each disease, we assessed correlations between these markers and disease severity (Expanded Disability Status Scale [EDSS]) scores according to three age groups (≤44, 45–54, and ≥55 years). RESULTS: Although serum GFAP levels were significantly higher in patients with NMOSD than those with MS, levels of both serum markers revealed significant positive correlations with EDSS scores in both diseases. In MS patients, the degrees of correlation between serum NfL (or GFAP) levels and EDSS scores were similar across all age groups. However, in NMOSD patients, positive GFAP‐EDSS correlations were distinctively stronger in the youngest than in the oldest group. Conversely, there were no positive NfL‐EDSS correlations in NMOSD in the youngest group, but there were significant in the oldest group. INTERPRETATION: The degrees to which serum NfL and GFAP levels reflect disease severity vary significantly with patient age in NMOSD, but not in MS. These findings suggest that the pathological processes and progression differ between the diseases; hence, serum biomarker levels may need to be interpreted differently according to patient age and disease type. John Wiley and Sons Inc. 2020-06-04 /pmc/articles/PMC7317646/ /pubmed/32495489 http://dx.doi.org/10.1002/acn3.51070 Text en © 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Lee, Eun‐Jae
Lim, Young‐Min
Kim, Seungmi
Choi, Lynkyung
Kim, Hyunjin
Kim, Keonwoo
Kim, Hye Weon
Lee, Ji Sung
Kim, Kwang‐Kuk
Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases
title Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases
title_full Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases
title_fullStr Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases
title_full_unstemmed Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases
title_short Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases
title_sort clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317646/
https://www.ncbi.nlm.nih.gov/pubmed/32495489
http://dx.doi.org/10.1002/acn3.51070
work_keys_str_mv AT leeeunjae clinicalimplicationofserumbiomarkersandpatientageininflammatorydemyelinatingdiseases
AT limyoungmin clinicalimplicationofserumbiomarkersandpatientageininflammatorydemyelinatingdiseases
AT kimseungmi clinicalimplicationofserumbiomarkersandpatientageininflammatorydemyelinatingdiseases
AT choilynkyung clinicalimplicationofserumbiomarkersandpatientageininflammatorydemyelinatingdiseases
AT kimhyunjin clinicalimplicationofserumbiomarkersandpatientageininflammatorydemyelinatingdiseases
AT kimkeonwoo clinicalimplicationofserumbiomarkersandpatientageininflammatorydemyelinatingdiseases
AT kimhyeweon clinicalimplicationofserumbiomarkersandpatientageininflammatorydemyelinatingdiseases
AT leejisung clinicalimplicationofserumbiomarkersandpatientageininflammatorydemyelinatingdiseases
AT kimkwangkuk clinicalimplicationofserumbiomarkersandpatientageininflammatorydemyelinatingdiseases